This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies

This study has been terminated.
Information provided by:
Bristol-Myers Squibb Identifier:
First received: September 12, 2005
Last updated: February 27, 2010
Last verified: July 2008
The purpose of this clinical research study is to learn about the safety and tolerability of daily BMS-275183 in patients with advanced cancer.

Condition Intervention Phase
Tumors Drug: BMS-275183 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies

Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • Safety and Tolerability

Secondary Outcome Measures:
  • PK, preliminary evidence of antitumor activity

Estimated Enrollment: 60
Study Start Date: October 2004
Primary Completion Date: February 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Non-hematologic malignancy that has progressed or no standard therapy is known
  • Four weeks from last chemotherapy or two weeks from last non-cytotoxic therapy
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
  • No more than 3 prior chemotherapy regimens in advanced/metastatic setting
  • Absolute neutrophil count >=1,500/mm3 and platelets >=100,000/mm3
  • Bilirubin <=1.5 x Upper Limit of Normal (ULN), Aspartate aminotransferase <=2.5 x ULN
  • Serum creatinine <=1.5 x ULN
  • Men and women >=18 years
  • Women of Child Bearing Potential (WOCBP) must use adequate method of contraception throughout and up to 4 weeks after the study

Exclusion Criteria:

  • WOCBP and men not using adequate method of birth control
  • WOCBP who are pregnant or breastfeeding
  • Prior radiation >=25% of bone marrow containing skeleton
  • Uncontrolled, significant, or active cardiovascular or pulmonary disease or infection or psychiatric disorder
  • Neuropathy
  • Active brain metastases
  • Inability to swallow capsules
  • History of gastrointestinal disease, surgery or malabsorption, or requiring use of a feeding tube
  • Concurrent chemotherapy, hormonal therapy, immunotherapy, or radiotherapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00207025

United States, Michigan
Local Institution
Detroit, Michigan, United States
United States, Pennsylvania
Local Institution
Pittsburgh, Pennsylvania, United States
Local Institution
Brussels, Belgium
Sponsors and Collaborators
Bristol-Myers Squibb
  More Information

Additional Information: Identifier: NCT00207025     History of Changes
Other Study ID Numbers: CA165-012
Study First Received: September 12, 2005
Last Updated: February 27, 2010

Keywords provided by Bristol-Myers Squibb:
Patients with advanced solid tumors processed this record on September 19, 2017